Hemophilia gene therapy: first, do no harm
Journal of Thrombosis and Haemostasis · 2023
DOI: 10.1016/j.jtha.2023.06.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Leonard A Valentino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rush University, Chicago, Illinois, USA; National Hemophilia Foundation, New York, New York, USA. Electronic address: whybloodclots@gmail.com. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Spark Therapeutics.
Abstract (Originalsprache)
The introduction of adeno-associated virus-mediated, liver-directed gene therapy into the hemophilia treatment landscape brings not only great promise but also considerable uncertainty to a community that has a history punctuated by the devastating effects of HIV and hepatitis C virus. These infections were introduced into people with hemophilia through the innovation of factor concentrates in the 1970s and 1980s. Concentrates, heralded as a major advance in treatment at the time, brought devastation and death to the community already challenged by the complications of bleeding into joints, vital organs, and the brain. Over the past 5 decades, considerable advances in hemophilia treatment have improved the survival, quality of life, and participation of people with hemophilia, although challenges remain and health equity with their unaffected peers has not yet been achieved. The decision to take a gene therapy product is one in which an informed, holistic, and shared decision-making approach must be employed. Bias on the part of health care professionals and people with hemophilia must be addressed and minimized. Here, we review data leading to the regulatory authorization of valoctocogene roxaparvovec, an adeno-associated virus 5 gene therapy, in Europe to treat hemophilia A and etranacogene dezaparvovec-drlb in the United States and Europe to treat hemophilia B. We also provide an overview of the decision-making process and recommend steps that should be taken by the hemophilia community to ensure the safety of and optimal outcomes for people with hemophilia who choose to receive a gene therapy product.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rush University, Chicago, Illinois, USA; National Hemophilia Foundation, New York, New York, USA. Electronic address: whybloodclots@gmail.com.
- Indiana University School of Medicine, Indianapolis, Indiana, USA; Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.
- World Federation of Hemophilia, Montreal, Quebec, Canada.
- European Haemophilia Consortium, Brussels, Belgium; Irish Haemophilia Society, Dublin, Ireland.
- Irish Haemophilia Society, Dublin, Ireland; Trinity College, Dublin, Ireland.
- Canadian Hemophilia Society, Montreal, Quebec, Canada.
Förderung
- Bayer
- Spark Therapeutics
Zitieren
APA
Valentino, L. A., Kaczmarek, R., Pierce, G. F., Noone, D., O'Mahony, B., Page, D., Rotellini, D., & Skinner, M. W. (2023). Hemophilia gene therapy: first, do no harm. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.06.016
Vancouver
Valentino LA, Kaczmarek R, Pierce GF, Noone D, O'Mahony B, Page D, et al. Hemophilia gene therapy: first, do no harm. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.06.016
BibTeX
@article{Valentino2023,
author = {Valentino, Leonard A and Kaczmarek, Radoslaw and Pierce, Glenn F and Noone, Declan and O'Mahony, Brian and Page, David and Rotellini, Dawn and Skinner, Mark W},
title = {Hemophilia gene therapy: first, do no harm},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
doi = {10.1016/j.jtha.2023.06.016}
}
EUVIMED